iBio, Inc. financial data

Symbol
IBIO on NYSE
Industry
Pharmaceutical Preparations
Location
600 Madison Avenue, Suite 1601, New York, NY
State of incorporation
DE
Fiscal year end
June 30
Former names
iBioPharma, Inc. (to 8/14/2009), InB:Biotechnologies, Inc. (to 7/17/2008)
Latest financial report
10-Q - Q4 2024 - Feb 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 215 % +93.6%
Quick Ratio 0 %
Debt-to-equity 60.7 % -67.2%
Return On Equity -198 % -28%
Return On Assets -69.4 % +24.9%
Operating Margin -53.6K % -2906%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.87M shares +183%
Common Stock, Shares, Outstanding 9.17M shares +183%
Entity Public Float 4.43M USD -18.5%
Common Stock, Value, Issued 9K USD -70%
Weighted Average Number of Shares Outstanding, Basic 9.13M shares +392%
Weighted Average Number of Shares Outstanding, Diluted 9.13M shares +392%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50K USD -97.2%
Revenue from Contract with Customer, Excluding Assessed Tax 200K USD
Research and Development Expense 5.23M USD -35.8%
General and Administrative Expense 10.7M USD -15.3%
Operating Income (Loss) -15.6M USD +25%
Nonoperating Income (Expense) 1.33M USD +588%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -4.36M USD +46.9%
Earnings Per Share, Basic 1.78 USD/shares +89.1%
Earnings Per Share, Diluted 1.78 USD/shares +89.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.02M USD +152%
Cash, Cash Equivalents, and Short-term Investments 6.43M USD -34.5%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD
Assets, Current 8.29M USD -57.9%
Property, Plant and Equipment, Net 3.39M USD -12.8%
Operating Lease, Right-of-Use Asset 2.23M USD -13.1%
Intangible Assets, Net (Excluding Goodwill) 6.11M USD +13.6%
Assets 21.7M USD -36.2%
Accounts Payable, Current 614K USD -67%
Employee-related Liabilities, Current 1.57M USD -59.6%
Accrued Liabilities, Current 1.84M USD -51.2%
Contract with Customer, Liability, Current 600K USD
Liabilities, Current 4.71M USD -78.2%
Operating Lease, Liability, Noncurrent 2.45M USD -15.9%
Liabilities 7.8M USD -68.6%
Retained Earnings (Accumulated Deficit) -322M USD -6.37%
Stockholders' Equity Attributable to Parent 13.9M USD +51.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 13.9M USD +51.1%
Liabilities and Equity 21.7M USD -36.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.72M USD +30.4%
Net Cash Provided by (Used in) Financing Activities -162K USD -107%
Net Cash Provided by (Used in) Investing Activities 713K USD +1326%
Common Stock, Shares Authorized 275M shares 0%
Common Stock, Shares, Issued 9.17M shares +183%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.16M USD -12.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.24M USD +78.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 57K USD -71.5%
Deferred Tax Assets, Valuation Allowance 54.9M USD +10.7%
Depreciation 120K USD -27.3%
Lessee, Operating Lease, Liability, to be Paid 3.5M USD +5.17%
Property, Plant and Equipment, Gross 4.64M USD +0.54%
Operating Lease, Liability, Current 462K USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 679K USD +47%
Lessee, Operating Lease, Liability, to be Paid, Year One 658K USD +59.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 698K USD +34.7%
Deferred Tax Assets, Operating Loss Carryforwards 49.1M USD +14.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 720K USD +24.8%
Operating Lease, Payments 563K USD -0.18%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 20K USD 0%
Share-based Payment Arrangement, Expense 1.65M USD -19.1%
Interest Expense 52K USD +48.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%